Information Provided By:
Fly News Breaks for December 17, 2019
Dec 17, 2019 | 12:56 EDT
JMP Securities analyst Jason Butler noted that Adamas Pharmaceuticals' phase 3 multiple sclerosis walking impairment trial of ADS-5102 met its primary endpoint but fell short of management's threshold to quickly advance to a second pivotal study. The analyst, who remains confident in management's ongoing efforts to optimize and reinvigorate Gocovri commercialization in levodopa-induced dyskinesia, reiterates his Outperform rating and $16 price target on Adamas, which does not include the MS walking indication.
News For ADMS From the Last 2 Days
There are no results for your query ADMS